Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4315537 | 0.86 | IDO1 (0.60) | VCAM1CYP2C19IDO1PKMLMNA | |
| SCHEMBL5034929 | 0.81 | CYP19A1 (0.74) | CYP2C19IDO1PKMLMNASMN1; SMN2 | |
| SCHEMBL13239651 | 0.78 | VCAM1 (0.77) | VCAM1CYP2C19LMNAMAPTSMN1; SMN2 | |
| SCHEMBL7207368 | 0.77 | POLB (0.55) | CYP2C19IDO1PKMMAPTSMN1; SMN2 | |
| SCHEMBL17085966 | 0.76 | VCAM1 (0.77) | VCAM1PKMMAPTSMN1; SMN2MEN1 | |
| SCHEMBL4319739 | 0.75 | IDO1 (0.68) | CYP2C19IDO1PKMLMNAMAPT | |
| SCHEMBL22456624 | 0.75 | MAPT (0.76) | PKMLMNAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL6261490 | 0.74 | VCAM1 (1.00) | VCAM1 | |
| SCHEMBL28496538 | 0.74 | VCAM1 (0.74) | VCAM1LMNAHTT | |
| SCHEMBL1876581 | 0.74 | IDO1 (0.70) | CYP2C19IDO1LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569688-B2 | Propane-1, 3-dione derivative | ASTELLAS PHARMA INC. (JP) | 2009-08-04 | — | — | US | disclosed |
| EP-1300398-B1 | PROPANE-1,3-DIONE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-20050267110-A1 | Propane-1, 3-dione derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2005-12-01 | — | — | US | disclosed |
| US-6960591-B2 | Propane-1,3-dione derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20030191164-A1 | Propane-1,3-dione derivatives | ASTELLAS PHARMA INC. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1300398-A1 | PROPANE-1,3-DIONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191164-A1 | Propane-1,3-dione derivatives | GNRHR, GPER1, FSHR | VCAM1 3121/4885CYP2C19 858/4885IDO1 1607/4885 |
| US-20050267110-A1 | Propane-1, 3-dione derivative | GNRHR, GPER1, FSHR | VCAM1 3061/4885CYP2C19 815/4885IDO1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.